6.4 ASTCT CRS Grading, Tocilizumab & Escalation Management
Key Takeaways
- ASTCT establishes initial CRS with fever >=38.0°C, then grades by hypotension and hypoxia support; after antipyretic or anticytokine treatment, fever need not persist for subsequent grading.
- Grading is driven by the level of hemodynamic and respiratory support required, so a patient whose hypotension resolves with a fluid bolus is graded differently from one requiring vasopressors.
- ASTCT grades severity but does not prescribe therapy; use the current product label and center pathway for tocilizumab, corticosteroids, antimicrobials, oxygen, fluids, vasopressors, and escalation.
- Refractory inflammation requires reassessment for infection, IEC-HS, cardiac and other mimics; anakinra, siltuximab, or other agents are off-label or protocol-specific rather than automatic grade-based steps.
1. The 2019 ASTCT Consensus CRS Grading System
In 2019, the American Society for Transplantation and Cellular Therapy (ASTCT) published consensus criteria to harmonize grading across all clinical trials and clinical practice. ASTCT CRS grading is strictly based on three parameters: Fever, Hypotension, and Hypoxia.
The ASTCT temperature rule: A temperature >=38.0°C not attributable to another cause is required to establish the initial CRS diagnosis. After CRS is established and antipyretic or anticytokine therapy is given, fever is no longer required for subsequent grading; grade follows the current hypotension and hypoxia support.
| ASTCT CRS Grade | Temperature Requirement | Hypotension Criteria | Hypoxia Criteria | Clinical Summary |
|---|---|---|---|---|
| Grade 1 | Fever >= 38.0°C | None | None | Fever alone; hemodynamically stable on room air. |
| Grade 2 | Fever >= 38.0°C | Hypotension NOT requiring vasopressors (responds to IV fluid challenge) | AND/OR Hypoxia requiring low-flow nasal cannula (<= 6 L/min) | Fluid-responsive hypotension and/or low-flow oxygen requirement. |
| Grade 3 | Fever >= 38.0°C | Hypotension requiring ONE vasopressor with or without vasopressin | AND/OR Hypoxia requiring high-flow nasal cannula (> 6 L/min), facemask, non-rebreather, or Venturi mask | Vasopressor-dependent shock (single pressor) and/or high-flow oxygen requirement. |
| Grade 4 | Fever >= 38.0°C | Hypotension requiring MULTIPLE vasopressors (excluding vasopressin) | AND/OR Hypoxia requiring positive airway pressure (CPAP, BiPAP, intubation and mechanical ventilation) | Life-threatening refractory shock (>= 2 pressors) and/or mechanical ventilatory support. |
Note on Vasopressin: Vasopressin is considered an adjunct; the requirement for a primary pressor (such as norepinephrine) plus vasopressin is classified as Grade 3. The requirement for two high-dose catecholaminergic vasopressors (such as norepinephrine + epinephrine or phenylephrine) constitutes Grade 4. Note on Organ Toxicities: Non-hemodynamic/pulmonary organ toxicities (such as renal failure, hepatic transaminitis) are graded according to CTCAE v5.0 but do not define or alter the ASTCT CRS grade.
2. Product- and Protocol-Directed Management
ASTCT defines the grade; it does not publish a treatment algorithm. Management depends on the product label, center pathway, rate of progression, comorbidity, concurrent ICANS, and infection differential.
- Immediate priorities: Stabilize airway/breathing/circulation, obtain the indicated infectious evaluation and antimicrobials, use cautious fluid assessment, and escalate vasopressor/oxygen/critical care support by physiology.
- Tocilizumab: This IL-6-receptor blocker is label-supported for severe or life-threatening CAR T-associated CRS and is used earlier in many institutional pathways. Verify the product/center indication, weight-based dose, maximum, repeat interval, and dose limit rather than applying one memorized schedule. Current CAR T labels direct the team to confirm two doses are available before infusion even though the FDA retired CAR T REMS in June 2025.
- Corticosteroids: Add or escalate under the product/center algorithm for progressive or refractory CRS and when concurrent ICANS requires CNS-active therapy. Choice, dose, interval, and taper reflect severity and response; do not withhold lifesaving therapy from fear of impairing cellular efficacy.
- Refractory inflammation: Recheck infection, cardiac/vascular, HLH-like/IEC-HS, and other mimics. Anakinra, siltuximab, other immune-directed agents, or extracorporeal/critical-care support may be used off-label in specialist pathways or trials; none is an automatic ASTCT Grade 4 regimen.
Clinical response is assessed from hemodynamics, oxygen, fever trajectory, organ function, and overall status—not an isolated CRP, ferritin, or IL-6 value.
3. Nursing Assessment and Hemodynamic Support
Monitor temperature, blood pressure, heart rate/rhythm, respiratory status, oxygen need, mental status, fluid balance, weight, perfusion and organ function at the label- and acuity-defined interval. Escalate any rapid change. Obtain indicated infection studies and antimicrobials without delaying stabilization or anti-CRS care.
Use small, reassessed crystalloid boluses when appropriate because capillary leak and cardiac dysfunction increase overload risk. Begin vasopressor, oxygen/ventilatory and critical-care support according to physiology and the sepsis/CRS pathway rather than a fixed fluid volume or central-line requirement. Administer antipyretics only as ordered after the fever has been recognized and evaluated; avoid NSAIDs when thrombocytopenia, bleeding or renal injury makes them unsafe.
4. Grading Worked Examples and the Common Traps
Grading errors are usually mechanical rather than conceptual, so working through the assignment on concrete cases is more useful than rereading the table.
Case A. Day +3 after CD19 CAR T. Temperature 38.6 degrees Celsius, blood pressure 118/70 mmHg with no fluid requirement, room air. Fever alone with no hypotension and no hypoxia is Grade 1.
Case B. Day +4. Temperature 39.1 degrees Celsius, blood pressure 84/50 mmHg that corrects with a fluid bolus and stays corrected, oxygen 3 L/min by nasal cannula. Hypotension not requiring vasopressors, with low-flow oxygen, is Grade 2.
Case C. Day +5. The patient received acetaminophen and tocilizumab and is now afebrile, but requires norepinephrine plus vasopressin and 10 L/min by high-flow nasal cannula. Fever is not required once CRS is established and treatment has begun, one primary vasopressor with vasopressin counts as a single pressor, and this is Grade 3.
Case D. Day +6. Norepinephrine and epinephrine are both infusing and the patient is intubated. Two catecholaminergic vasopressors, or positive pressure ventilation, define Grade 4.
Case E. Day +5. Temperature 38.4 degrees Celsius, normal blood pressure, room air, creatinine risen from 0.8 to 2.4 mg/dL and ALT four times the upper limit of normal. Organ toxicity is graded separately under CTCAE and does not raise the ASTCT CRS grade. This remains Grade 1 CRS with concurrent organ toxicity requiring its own management.
The traps worth naming: hypoxia is graded by the support device required, not by a saturation value, so a patient at 91 percent on room air is not automatically graded higher than one at 96 percent on high-flow oxygen; hypotension is graded by whether vasopressors are needed, not by the blood pressure number; vasopressin is an adjunct rather than a second pressor; and the grade tracks the current support requirement, so it falls as the patient improves rather than remaining at its peak.
A 62-year-old male received brexucabtagene autoleucel 2 days ago. He has fever and hypotension that resolves after an IV fluid bolus, with SpO2 96% on room air. What is the ASTCT CRS grade, and which product/center-protocol action is reasonable while infection is evaluated?
A patient has progressive ASTCT grade 3 CRS despite initial anti-IL-6 treatment, with one vasopressor and high-flow oxygen. What is the best next principle?
Before antipyretic or anticytokine treatment has suppressed the temperature, which finding is required to establish the initial ASTCT CRS diagnosis?